| 1 |
高振秋，王东方，任成山. 耐多药结核病临床研究的回顾与展望[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3(5): 353-363.
|
| 2 |
王细文，胡明冬. 耐多药结核病—预防和控制的关键步骤[J/CD]. 中华肺部疾病杂志(电子版), 2010, 3(6): 443-450.
|
| 3 |
方源扬，刘国强，黄显聪，等. 景东县2004－2013年肺结核防治的卫生经济学分析[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(1): 36-40.
|
| 4 |
何娅，肖和平. 结核病诊治的百年回顾[J]. 上海医学，2017, 40(2): 73-75.
|
| 5 |
马爱静，赵雁林. 耐药结核病的监测现状[J]. 中国抗生素杂志，2018, 43(5): 502-506.
|
| 6 |
World Health Organization. Global tubercoulosis report 2017. 2017, World Health Organiztion, Geneva, Switzerland.
|
| 7 |
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling[J]. PLoS Med, 2016, 13: e1002152.
|
| 8 |
Global Tuberculosis Report 2018. WHO, 2018: 7-149.
URL
|
| 9 |
WHO. Global tuberculosis report 2017. 2017. accessed March 11, 2019)．
URL
|
| 10 |
Satyaprakash S, Maruti YH, Shashidhar B. Role of flexible bronchoscopy in patients with sputum-negative pulmonary tuberculosis[J]. Indian J Thorac Cardiovasc Surg,
URL
|
| 11 |
Ismail NA, Mvusi L, Nanoo A, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey[J]. Lancet Infect Dis, 2018, 18: 779-787.
|
| 12 |
GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study[J]. Lancet Infect Dis, 2018, 18: 1329-1349.
|
| 13 |
Mehra M, Cossrow N, Kambili C, et al. Assessment of tuberculosis burden in China using a dynamic disease simulation model[J]. Int J Tuberc Lung Dis, 2013, 17: 1186-1194.
|
| 14 |
Trauer JM, Denholm JT, McBryde ES. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-Pacific[J]. J Theor Biol, 2014, 358: 74-84.
|
| 15 |
Law S, Piatek AS, Vincent C, et al. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study[J]. Lancet Public Health, 2017, 2: e47-55.
|
| 16 |
Drain P, Bajema K, Dowdy D, et al. Incipient and sub-clinical tuberculosis：a clinical review of early stages and progression of infection[J]. Clinical Microbiol Rev, 2018, 31: e00021-18.
|
| 17 |
Michelsen SW, Soborg B, Diaz LJ, et al. The dynamics of immune responses to Mycobacterium tuberculosis during different stages of natural infection: a longitudinal study among Greenlanders[J]. PLoS One, 2017, 12: e0177906.
|
| 18 |
Torrelles J, Schlesinger L. Integrating lung physiology, immunology and tuberculosis[J]. Trends Microbiol, 2017, 25: 688-697.
|
| 19 |
Seshadri C, Sedaghat N, Campo M, et al. Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection[J]. PLoS One, 2017, 12: e0175844.
|
| 20 |
Shah NS, Auld S, Brust J, et al. Transmission of extensively drug-resistant tuberculosis in South Africa[J]. N Engl J Med, 2017, 376: 243-253.
|
| 21 |
Dheda K, Lenders L, Magombedze G, et al. Drug penetration gradients associated with acquired drug resistance in patients with tuberculosis[J]. Am J Respir Crit Care Med, 2018, 198: 1208-1219.
|
| 22 |
Oxlade O, Murray M. Tuberculosis and poverty: why are the poor at greater risk in India？[J]. PLoS One, 2012, 7: e47533.
|
| 23 |
Ortblad K, Salomon J, Barnighause T, et al. Stopping tuberculosis: a biosocial model for sustainable development[J]. Lancet, 2015, 386: 2354-2362.
|
| 24 |
Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study[J]. Lancet Infect Dis, 2017, 17: 1190-1199.
|
| 25 |
Batista JdL, de Albuquerque Mde F, Maruza M, et al. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil[J]. PLoS One, 8: e63916.
|
| 26 |
Lonnroth K, Jaramillo E, Williams BG, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants[J]. Soc Sci Med, 2009, 68: 2240-2246.
|
| 27 |
World Health Organization. Global tuberculosis report 2016. 2016, World Health Organization, Geneva, Swizerland.
|
| 28 |
Javaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country[J]. Eur Respir J, 2017, 49(1). pii：1601967.
|
| 29 |
WHO Guidelines Approved by the Guidelines Review Committee. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
|
| 30 |
Chien JY, Wang JY. Isoniazid-resistant tuberculosis treatment with first-line drugs[J]. Lancet Infect Dis, 2017, 17: 259-260.
|
| 31 |
International Union Against Tuberculosis and Lung Disease. Guidelines for the clinical and operational management of durgresistant tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease, 2013.
|
| 32 |
Coovadia YM, Mahomed S, Pillay M, et al. Rifampicin mono-resistance in mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region[J]. PLoS One, 2013, 8: e77712.
|
| 33 |
WHO. Guidelines on the treatment of isoniazid-resistant tuberculosis. 2017. accessed Nov 9, 2018)．
URL
|
| 34 |
张怡，孙峰，张文宏. 耐多药结核病治疗指南的发展趋势[J]. 中国防痨杂志，2018, 40(2): 135-139.
|
| 35 |
Md Arifur R, Atanu S. Extensively Drug-resistant Tuberculosis (XDR-TB): A daunting challenge to the current End TB Strategy and policy recommendations[J]. Indian J Tuberculosis,
URL
|
| 36 |
Migliori G, Mattelli A, Cirillo D, Pai M. Diagnosis of multidrug-resistant tuberculosis and extensively drugresistant tuberculosis: current standards and challenges[J]. Can J Infect Dis Med Microbiol, 2008, 19(2): 169-172.
|
| 37 |
CDC. XDR TB-Centers for Disease Control and Prevention. Center for Disease Control; 2015 cited 15.09.16]．
URL
|
| 38 |
World Health Organization. Global tuberculosis report 2016. Geneva：WHO; 2016 cited13.02.17]．
URL
|
| 39 |
Walker BR, Colledge NR, Ralston SH, et al. Tuberculosis in Davidson′s Principle and Practice of Medicine. 22nd ed. Churchill Livingstone publication Ltd. 2014: 643-732[chapter19]．
|
| 40 |
WHO. The Paradigm Shift: 2016-2020. Global Plan to End TB. World Health Organization; 2016
URL
|
| 41 |
Pai M. The End TB Strategy: India can blaze the trail[J]. Indian J Med Res, 2015, 141(3): 259-262.
|
| 42 |
WHO. Implementing the Stop TB strategy: A Handbook for National Tuberculosis Control Programs. Geneva: World Health Organization; 2008
URL
|
| 43 |
Anastasia K, Helen C, Valerie M. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment[J]. Current Opinion in Pharmacology, 2018, 42: 7-15.
|
| 44 |
Rubin EJ: TB diagnosis from the dark ages to fluorescence[J]. Nat Microbiol, 2018, 3: 268-269.
|
| 45 |
Trauner A, Liu Q, Via LE, et al. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy[J]. Genome Biol, 2017, 18: 71.
|
| 46 |
Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study[J]. Lancet Infect Dis, 2015, 15: 1193-1202.
|
| 47 |
Desjardins CA, Cohen KA, Munsamy V, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance[J]. Nat Genet, 2016, 48: 544-551.
|
| 48 |
Coll F, Phelan J, Hill-Cawthorne GA, et al. Genome-wide analysis of multi-and extensively drug-resistant Mycobacterium tuberculosis[J]. Nat Genet, 2018, 50(2): 307-316.
|
| 49 |
Heyckendorf J, Andres S, Koser CU, et al. What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis[J]. Antimicrob Agents Chemother, 2018, 62(2): pii: e01550-17.
|
| 50 |
Denise RS, Margareth D, Simon T, et al. New and repurposed drugs to treat multidrug-and extensively drug-resistant tuberculosis[J]. J Bras Pneumol, 2018, 44(2): 153-160.
|
| 51 |
Pontali E, Sotgiu G, D′Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence[J]. Eur Respir J, 2016, 47(2): 394-402.
|
| 52 |
Pontali E, D′Ambrosio L, Centis R, et al. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline[J]. Eur Respir J, 2017, 49(3). pii: 1700146.
|
| 53 |
DR-TB Scale-Up Treatment Action Team (DR-TB STAT) [homepage on the Internet].
URL
|
| 54 |
ClinicalTrials. gov [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [updated 2016 Oct 26; cited 2017Nov 21]. An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NEXT); Identifier NCT02454205; [about 14 screens]. Available from:
URL
|
| 55 |
ClinicalTrials.gov [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [updated 2018 Jan 11; cited 2017 Nov 21]. The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM); Identifier NCT02409290; [about 22 screens]. Available from:
URL
|
| 56 |
ClinicalTrials.gov [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [updated 2017 Jan 18; cited 2017Nov 21]. Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (TB-PRACTECAL); Identifier NCT02589782; [about 14 screens]. Available from:
URL
|
| 57 |
ClinicalTrials.gov [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [updated 2017 Nov 17; cited 2017Oct 15]. Evaluating Newly Approved Drugs for Multidrug-resistantTB (endTB); Identifier NCT02754765; [about 16 screens]. Available from:
URL
|
| 58 |
Dawson R, Harris K, Conradie A, et al. Efficacy of Bedaquiline, Pretomanid, Moxifloxacin & PZA (BPAMZ) Against DS-& MDR-TB. In: Conference on Retroviruses and Opportunistic Infections [proceedings on the Internet]; 2017 Feb 13-16; Seattle, Washington. Abstract Number 724LB. [cited 2017 Oct 18]. Available from:
URL
|
| 59 |
Aung K, Van Deun A, Declerq E, et al. Successful '9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients[J]. Int J Tuberc Lung Dis, 2014, (18): 1180-1187.
URL
|
| 60 |
Piubello A, Harouna S, Souleymane MB, et al. High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses[J]. Int J Tuber Lung Dis, 2014, (18): 1188-1194.
|
| 61 |
Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 2017, 49(3)．pii: 1602308.
|
| 62 |
|
| 63 |
Melese M, Habte D, Girma B, et al. Use of indicators of standards of care to improve tuberculosis program management in Ethiopia[J]. J Clin Tuberc Other Mycobact Dis, 2018, 10: 17-23.
|
| 64 |
WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019, 1-104,
URL
|
| 65 |
Furiu J, Cox H, Pai M. Tuberculosis[J]. Published online, 2019
URL
|